{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=atezolizumab&page=32", "query": { "intervention": "atezolizumab", "page": 32 }, "page_size": 10 }, "pagination": { "page": 32, "page_size": 10, "total_count": 512, "total_pages": 52, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=atezolizumab&page=33&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=atezolizumab&page=31&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T12:36:32.361Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05645692", "title": "A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Tobemstomig", "type": "DRUG" }, { "name": "Tiragolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 204, "start_date": "2023-04-13", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-10-31T12:36:32.361Z", "location_count": 2, "location_summary": "Cleveland, Ohio • Houston, Texas", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05645692" }, { "nct_id": "NCT02220842", "title": "A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Tazemetostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2014-12-18", "completion_date": "2020-01-21", "has_results": false, "last_update_posted_date": "2020-01-27", "last_synced_at": "2026-10-31T12:36:32.361Z", "location_count": 7, "location_summary": "Duarte, California • Fort Wayne, Indiana • Hackensack, New Jersey + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02220842" }, { "nct_id": "NCT06117891", "title": "An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Unresectable Hepatocellular Carcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Tremelimumab,", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2023-11-27", "completion_date": "2026-12-10", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-10-31T12:36:32.361Z", "location_count": 6, "location_summary": "Baltimore, Maryland • Ann Arbor, Michigan • Buffalo, New York + 2 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Buffalo", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06117891" }, { "nct_id": "NCT03409016", "title": "Biomarkers of Immune-Related Toxicity", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer", "Metastatic Cancer" ], "interventions": [ { "name": "Blood Testing", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 69, "start_date": "2018-04-18", "completion_date": "2026-10-17", "has_results": false, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-10-31T12:36:32.361Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03409016" }, { "nct_id": "NCT04829383", "title": "A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Unresectable Hepatocellular Carcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Howard S Hochster", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2021-03-22", "completion_date": "2024-10-15", "has_results": true, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-10-31T12:36:32.361Z", "location_count": 7, "location_summary": "Chicago, Illinois • Indianapolis, Indiana • Omaha, Nebraska + 4 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04829383" }, { "nct_id": "NCT07707895", "title": "DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small Cell Lung Cancer", "Large Cell Neuroendocrine Lung Carcinoma", "Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology", "Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology" ], "interventions": [ { "name": "Obrixtamig", "type": "DRUG" }, { "name": "ZL-1310", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2026-10-28", "completion_date": "2030-04-26", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-10-31T12:36:32.361Z", "location_count": 3, "location_summary": "Washington D.C., District of Columbia • Tampa, Florida • Lexington, Kentucky", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT07707895" }, { "nct_id": "NCT05171777", "title": "A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 179, "start_date": "2022-04-04", "completion_date": "2024-10-25", "has_results": true, "last_update_posted_date": "2025-12-11", "last_synced_at": "2026-10-31T12:36:32.361Z", "location_count": 4, "location_summary": "Brick, New Jersey • Massillon, Ohio • Medford, Oregon + 1 more", "locations": [ { "city": "Brick", "state": "New Jersey" }, { "city": "Massillon", "state": "Ohio" }, { "city": "Medford", "state": "Oregon" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05171777" }, { "nct_id": "NCT03455556", "title": "Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mesothelin Positive", "Stage III Non-Small Cell Lung Cancer AJCC v7", "Stage IIIA Non-Small Cell Lung Cancer AJCC v7", "Stage IIIB Non-Small Cell Lung Cancer AJCC v7", "Stage IV Non-Small Cell Lung Cancer AJCC v7" ], "interventions": [ { "name": "Anetumab Ravtansine", "type": "BIOLOGICAL" }, { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2018-08-10", "completion_date": "2020-01-07", "has_results": true, "last_update_posted_date": "2023-01-06", "last_synced_at": "2026-10-31T12:36:32.361Z", "location_count": 3, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03455556" }, { "nct_id": "NCT03568656", "title": "Study to Evaluate CCS1477 in Advanced Tumours", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Castration-Resistant Prostate Cancer", "Metastatic Breast Cancer", "Non-small Cell Lung Cancer", "Advanced Solid Tumors" ], "interventions": [ { "name": "CCS1477", "type": "DRUG" }, { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CellCentric Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 219, "start_date": "2018-07-23", "completion_date": "2025-07-06", "has_results": true, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-31T12:36:32.361Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Philadelphia, Pennsylvania", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03568656" }, { "nct_id": "NCT04560686", "title": "Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Resectable Lung Non-Small Cell Carcinoma", "Stage I Lung Cancer AJCC v8", "Stage IA1 Lung Cancer AJCC v8", "Stage IA2 Lung Cancer AJCC v8", "Stage IA3 Lung Cancer AJCC v8", "Stage IB Lung Cancer AJCC v8", "Stage II Lung Cancer AJCC v8", "Stage IIA Lung Cancer AJCC v8", "Stage IIB Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Bintrafusp Alfa", "type": "DRUG" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2020-08-05", "completion_date": "2021-07-01", "has_results": true, "last_update_posted_date": "2022-07-28", "last_synced_at": "2026-10-31T12:36:32.361Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04560686" } ] }